TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01818882

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care for dyspneic patients including contextual analysis, conventional clinical exam and a chest X-Ray.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care for dyspneic patients including contextual analysis, conventional clinical exam and a chest X-Ray.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vscan portable ultrasound device (GE Healthcare, Wauwatosa, WI)
Description: Standard care (as described for the other intervention) + pleuropulmonary ultrasound using the Vscan portable ultrasound device (GE Healthcare, Wauwatosa, WI).
Study: NCT03266146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 36 Weeks Methylprednisolone
Description: Participants in 36 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 20 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 36 weeks. Follow-up duration is 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 48 weeks Methylprednisolone
Description: Participants in 48 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
Study: NCT01062425

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3-dimensional conformal radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3-dimensional conformal radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo intensity-modulated radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo intensity-modulated radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given PO
Study: NCT03691701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strict blood pressure control
Description: Home SBP target \< 120 mmHg or 90th percentile for age and height (whichever is lower)
Study: NCT02749188

Intervention type: OTHER
Group type: OTHER
Intervention: Bladder stimulation
Description: Bladder stimulation as a noninvasive technique of urine collection. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes
Study: NCT03421613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3VM1001
Description: Self treatment 3 times daily for 10 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cream without investigational drug. Self treatment 3 times daily for 10 days
Study: NCT03740217

Intervention type: DRUG
Group type: OTHER
Intervention: GKT137831
Description: oral bioavailable small molecule that selectively inhibit NOX1 and NOX4

Intervention type: DRUG
Group type: OTHER
Intervention: GKT137831
Description: oral bioavailable small molecule that selectively inhibit NOX1 and NOX4

Intervention type: DRUG
Group type: OTHER
Intervention: GKT137831
Description: oral bioavailable small molecule that selectively inhibit NOX1 and NOX4
Study: NCT02804607

Intervention type: OTHER
Intervention: questionnaire
Study: NCT00847873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: substance abuse/domestic violence treatment
Description: This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy addressing substance abuse
Description: This intervention is comprised of 16 sessions of cognitive behavioral therapy addressing substance abuse.
Study: NCT00523029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program
Description: Chronic disease self-management is a 6-week group program that teaches participants how to manage their chronic medical illness. Group leaders, also suffering from a chronic medical condition, will lead discussions based on the following topics: nutrition; exercise; appropriate use of medications; ways to communicate effectively with family, friends, and health care professionals; and how to make informed treatment decisions.
Study: NCT01260441

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPR Training using the Family and Friends CPR Anytime VSI Kit
Description: Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPR Training using the Family and Friends CPR Anytime VSI Kit
Description: Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
Study: NCT04402333

Intervention type: PROCEDURE
Intervention: Robotic Interval Debulking Surgery
Description: Interval debulking surgery carried out in a minimally invasive manner using the Da Vinci Robot.
Study: NCT04225845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone therapy
Description: Weekly phone calls by lay trained personnel to deliver problem solving therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone therapy
Description: Weekly phone calls by lay trained personnel to deliver problem solving therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash transfer
Description: One-time cash transfer of Rs.1000.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash transfer
Description: One-time cash transfer of Rs.1000.
Study: NCT01085318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif
Description: 44 mcg tiw
Study: NCT01224041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: oral
Study: NCT03062826

Intervention type: DRUG
Intervention: dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel)
Description: Patients who met the inclusion criteria will be treated with dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel).
Study: NCT01154634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516, 5 mg
Description: Capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516, 5 mg
Description: Capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516, 5 mg
Description: Capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516, 5 mg
Description: Capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516, 16 mg
Description: Capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516, 16 mg
Description: Capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516, 16 mg
Description: Capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516, 16 mg
Description: Capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516, 40 mg
Description: Capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516, 40 mg
Description: Capsule, oral
Study: NCT03747094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.25 mg ketamine will be administered immediately before the procedure
Study: NCT01154634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516, 40 mg
Description: Capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516, 40 mg
Description: Capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule, oral
Study: NCT02009618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin tablet is given as 200 mg 3x2/daily, for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01418300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sequential versus triple
Description: sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe lansoprazole 30mg bid+clarithromycin 500mg bid+amoxicillin 1000mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sequential versus triple
Description: sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe lansoprazole 30mg bid+clarithromycin 500mg bid+amoxicillin 1000mg bid
Study: NCT00319423

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient education and supervised exercise
Description: Patient education: 3 sessions Supervised exercise: 2-3 times/week for 12 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient education and supervised exercise
Description: Patient education: 3 sessions Supervised exercise: 2-3 times/week for 12 weeks
Study: NCT03384407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red cell survival in INTERCEPT treated red cells
Description: Red cell recovery/survival analysis of untreated and INTERCEPT treated RBC concomitantly
Study: NCT00568100

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV and NAVA
Description: evaluated the effect of PSV and NAVA on breathing pattern, respiratory effort, gas exchange and level of breathing comfort in COPD patients
Study: NCT03411226

Intervention type: PROCEDURE
Intervention: re-TREPP
Description: repeated hernia repair via the TREPP technique
Study: NCT04420299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemiparin
Description: Bemiparin at therapeutic dose for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemiparin
Description: Bemiparin at prophylactic dose for 10 days
Study: NCT02438241

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy Group
Description: Patients randomized to this group will receive only conventional physiotherapy. The treatment protocol Control Group, will consist of weathered active exercises to manually lower limbs in bed (triple flexion, abduction and adduction, plantar / dorsiflexion), free active exercises of the upper limbs in the bed (shoulder flexion, shoulder flexion and horizontal functional diagonal shoulder), bronchial hygiene techniques, flow redirection, positive expiratory pressure and ventilatory blowing patterns.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TENS Group
Description: Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), and the end of that service, will be applied TENS. TENS is accomplished through the use of an electrical stimulation device with symmetrical biphasic current pulse. The following parameters are used: frequency: 100 Hz, pulse width: 100 µs, intensity to the greatest sensory threshold of the patient and total session time: 30 minutes. Self-adhesive electrodes will be used (Valutrode, size 5x9 cm) to be positioned in the posterolateral portion of the chest to 2 cm skin incision both upper and lower.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TENS group
Description: Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), will be held the same procedure as TENS group, except that TENS will be offered to the patient only for 45 seconds, and in the first 30 seconds is reached the sensory threshold of the patient and in the last 15 seconds will turn off the electrical current by 29 remaining period minutes and 15 seconds off.
Study: NCT02479984

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Staging Laparoscopy
Description: Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis.~Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laparoscopic ultrasound
Study: NCT02662712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 oral tablets will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 oral tablets will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
Study: NCT01348659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7.2% NaCl/hydroxyethylstarch
Description: 250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) will be given into the venous reservoir of the cardiopulmonary bypass circuit after aortic declamping.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 0.9%
Description: 250 ml of NaCl 0.9% will be given into the venous reservoir of the CPB circuit after aortic declamping.
Study: NCT02662712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 oral tablets will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to JNJ-56136379 will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to JNJ-56136379 will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to JNJ-56136379 will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
Study: NCT01911052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone based re-education
Description: The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short message system based re-education
Description: The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
Study: NCT01153594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Management Checkups (RMC)
Description: After interviewers completed the quarterly research interview and determined participants' eligibility and need for early re-intervention, they transferred RMC participants who were eligible and in need to a Linkage Manager. Using motivational interviewing, the Linkage Manager: a) provided feedback to participants regarding their current substance use and related problems, b) discussed implications of managing addiction as a chronic condition, c) discussed treatment barriers and solutions, d) assessed and discussed level of motivation for treatment, e) scheduled treatment appointments, f) accompanied participants to treatment intake and stayed through the process, and g) implemented Engagement and Retention Protocol during the 14 days of treatment
Study: NCT04623801

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Laser Ablation (PLA)
Description: Percutaneous Laser Ablation / PLA will be carried out in a single session by advancing one 21-gauge spinal needle into the target lesions under real time US guidance.
Study: NCT00607841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ispinesib
Description: 10 mg/m2 dose as a 1-hour intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ispinesib
Description: 12 mg/m2 dose as a 1-hour intravenous infusion.
Study: NCT03539939

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally Advanced Flap
Description: The coronally advanced flap (CAF) is a procedure frequently used in periodontal plastic surgery. The main objective of this surgical technique is to mobilize the gingival margin and reposition it at a level more coronal (incisal direction) than its original location. CAF is mainly used for the treatment of gingival recessions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally Advanced Flap
Description: The coronally advanced flap (CAF) is a procedure frequently used in periodontal plastic surgery. The main objective of this surgical technique is to mobilize the gingival margin and reposition it at a level more coronal (incisal direction) than its original location. CAF is mainly used for the treatment of gingival recessions.
Study: NCT00607841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ispinesib
Description: 14 mg/m2 dose as a 1-hour intravenous infusion.
Study: NCT04209660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 20mg daily (two 10mg lenvatinib capsules) taken orally will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 20mg daily (two 10mg lenvatinib capsules) taken orally will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes are acceptable on C1D1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes are acceptable on C1D1.
Study: NCT03846024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RibFx Orthosis Belt
Description: Each patient in the interventional arm will be fitted with a RibFx orthosis belt, which is to be worn during the majority of their day (excluding showering/bathing). It will be encouraged (though not mandatory) to wear at night. Patients in both the control and interventional arm will be expected to participate in pulmonary hygiene / toilet exercises with guided and independent incentive spirometry as per our normal routine and standard of care. There are no other interventions or procedures that the patients will be subjected to for the research trial- other procedures/interventions will be performed only if the clinical care team feels they are indicated.
Study: NCT04279574

Intervention type: DEVICE
Group type: OTHER
Intervention: Lithium disilicate onlays (IPS emaxCAD/Ivoclar)
Description: Restoration of posterior teeth

Intervention type: DEVICE
Group type: OTHER
Intervention: Chairside zirconia crowns (3M)
Description: Restoration of posterior teeth
Study: NCT01055392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: lithium carbonate tablets, 150 mg to 450 mg (target serum lithium level 0.25 mEq/L - 0.5 mEq/L), divided in two doses, two years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo tablets were administered twice-a-day for two years.
Study: NCT02366572

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Non pulse extruded cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea protein
Description: Pulse extruded cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea starch
Description: Pulse extruded cereal
Study: NCT02643810

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
Study: NCT02366572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea fibre + pea starch
Description: Pulse extruded cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea protein + pea starch
Description: Pulse extruded cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea fibre + pea starch + pea protein
Description: Pulse extruded cereal